Latest Financial Position News

TerraCom Limited reported a statutory loss of A$33.7 million for FY2025 amid lower coal sales and prices, while progressing its Moorlands Thermal Coal Project in partnership with Wintime Energy Group.

OpenLearning Limited reported a 30% revenue increase for the half-year to June 2025, driven by expanded AI-powered LMS adoption and multi-year contracts in the Philippines, while working towards break-even despite a wider loss.

Excelsior Capital Limited reports a sharp 98% drop in profit after tax for FY25 following the prior year’s $47.2 million gain from selling its CMI Electrical subsidiary. Despite this, the company declared a fully franked final dividend of 4.0 cents per share.

Vectus Biosystems has posted a 58% drop in revenue and a 24% reduction in operating loss for FY2025, but its net equity has swung into negative territory.

RLF AgTech Ltd has reported a remarkable financial turnaround in FY25, with revenues more than doubling and losses narrowing significantly, setting the stage for expansion in FY26.

Clime Investment Management Limited has reported a significant turnaround in FY25, returning to profitability with a 13% revenue increase and proposing a fully franked final dividend. The company expanded its business lines and strengthened its leadership team, setting a positive outlook for FY26.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

AdNeo Limited reported a 14% rise in FY25 revenue driven by acquisitions, yet posted a $5.25 million net loss impacted by non-recurring items. Post-year-end capital raising and cost cuts position the company for growth.

BauMart Holdings Limited has dramatically reduced its net loss to $123,086 for the year ended June 2025, down from $4.68 million the previous year, as it advances strategic initiatives and strengthens its financial position through a rights issue.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.